The Lymphoma Research Foundation (LRF) is a U.S.-based non-profit organization dedicated exclusively to funding lymphoma research and providing support to patients, caregivers, and clinicians affected by Hodgkin and non-Hodgkin lymphoma. Founded in 1995 and headquartered in New York City, it is the nation’s largest such entity, having awarded more than $86 million in research grants since inception while serving over three million individuals through educational resources, community programs, and advocacy. Its mission centers on advancing scientific understanding to eradicate lymphoma.
Also known as Lymphoma Research Foundation of America.
Phase III CELESTIMO interim analysis showed a statistically significant, clinically meaningful PFS benefit versus rituximab+lenalidomide; OS immature; safety consistent with known profiles.
sBLA accepted based on phase III SUNMO showing 59% reduction in progression risk; FDA decision expected by 9 Feb 2027.
sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
